Several CTSK‐specific inhibitors directed at osteoporosis and osteoarthritis have been developed and tested clinically.[22] For example, odanacatib (ODN) was found to be most effective in treating osteoporosis and significantly increased bone mineral density in postmenopausal women.[23] Unfortunately, the drug was rejected in phase‐III clinical trials due to the increased risk for cardiovascular morbidity.[22, 23]. The gene discussed is CTSK; the disease is osteoporosis.